Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 31;15(2):212.
doi: 10.3390/life15020212.

Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients

Maria-Lorena Mustață  1 , Carmen-Daniela Neagoe  2 , Virginia-Maria Rădulescu  3 , Ioana-Gabriela Dragne  1 , Radu-Cristian Cîmpeanu  1 , Lucrețiu Radu  4 , Roxana-Viorela Ahrițculesei  1 , Dragoș Forțofoiu  1 , Maria-Cristina Predoi  5 , Simona-Laura Ianoși  6
Affiliations

Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients

Maria-Lorena Mustață et al. Life (Basel). .

Abstract

Background/objectives: Psoriasis is a chronic inflammatory autoimmune disease with important systemic and psychosocial impacts. The association with metabolic syndrome (MS) impairs disease severity and negatively influences patient-reported outcomes, particularly their quality of life as measured by the Dermatology Life Quality Index (DLQI). This study aims to investigate the relationship between systemic inflammation, DLQI scores and disease severity, focusing on the persistent impact of MS on patient outcomes after one year of treatment.

Methods: This retrospective cross-sectional study included 150 psoriasis patients, with 74 also meeting the diagnostic criteria for MS. Clinical and inflammatory markers such as systemic immune-inflammatory index (SII), cytokines (IL-17A, IL-23), leptin, BMI and triglycerides were analyzed alongside PASI and DLQI scores.

Results: Patients with MS had significantly higher PASI and DLQI scores compared to those without MS, reflecting worse disease severity and quality of life (p < 0.01). Elevated SII levels were strongly associated with higher DLQI scores (p < 0.01). Despite considerable reductions in PASI scores over one year of treatment, DLQI scores indicated a persistent negative impact of MS on quality of life. Notably, markers of systemic inflammation, such as SII, leptin and cytokines, correlated positively with both PASI and DLQI scores, highlighting the role of systemic inflammation in disease burden.

Conclusions: This study underlines the significant role of systemic inflammation and metabolic comorbidities in amplifying the burden of psoriasis. The persistent impact of MS on quality of life despite clinical improvement underscores the need for comprehensive treatment approaches targeting systemic inflammation, metabolic health and psychosocial factors to improve long-term outcomes.

Keywords: DLQI; PASI; leptin; metabolic syndrome; psoriasis; systemic inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Treatment distribution: (a) Distribution of treatment among all patients; (b) Distribution of treatment between PSO–MS and PSO groups.
Figure 2
Figure 2
DLQI correlation: (a) correlation for initial DLQI; (b) correlation for final DLQI.
See this image and copyright information in PMC

References

    1. Horn E.J., Fox K.M., Patel V., Chiou C.-F., Dann F., Lebwohl M. Association of Patient-Reported Psoriasis Severity with Income and Employment. J. Am. Acad. Dermatol. 2007;57:963–971. doi: 10.1016/j.jaad.2007.07.023. - DOI - PubMed
    1. Reich K. The Concept of Psoriasis as a Systemic Inflammation: Implications for Disease Management. J. Eur. Acad. Dermatol. Venereol. 2012;26:3–11. doi: 10.1111/j.1468-3083.2011.04410.x. - DOI - PubMed
    1. Elewski B., Alexis A.F., Lebwohl M., Stein Gold L., Pariser D., Del Rosso J., Yosipovitch G. Itch: An Under-Recognized Problem in Psoriasis. J. Eur. Acad. Dermatol. Venereol. 2019;33:1465–1476. doi: 10.1111/jdv.15450. - DOI - PubMed
    1. Pithadia D.J., Reynolds K.A., Lee E.B., Wu J.J. Psoriasis-Associated Itch: Etiology, Assessment, Impact, and Management. J. Dermatol. Treat. 2019;31:18–26. doi: 10.1080/09546634.2019.1572865. - DOI - PubMed
    1. Wintermann G., Bierling A.L., Peters E.M.J., Abraham S., Beissert S., Weidner K. Psychosocial Stress Affects the Change of Mental Distress under Dermatological Treatment—A Prospective Cohort Study in Patients with Psoriasis. Stress Health. 2024;40:e3263. doi: 10.1002/smi.3263. - DOI - PubMed

LinkOut - more resources